| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.04 | 0.4 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.4 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | 0.023 | 0.4 |